Protalix BioTherapeutics, Inc. (PLX) stock

PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3048% below fair value

$2.96−0.17 (-5.43%)

Close on Nov 12, 2026Market cap $238.49MP/E 11.8Yield –

Protalix BioTherapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Protalix BioTherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Protalix BioTherapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Dec 20, 2019
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing